2-(2-chloropyridin-4-yl)propan-2-amine | 259248-41-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(2-chloropyridin-4-yl)propan-2-amine
• CAS: 259248-41-4
• 化学式: C₈H₁₁ClN₂
• 分子量: 170.642
• InChiKey: IFVNKHQARILOLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-chloropyridin-4-yl)propan-2-amine 、 8-(tert-butylamino)-6-chloro-2-(2-hydroxyethyl)-2,7-naphthyridin-1(2H)-one 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 sodium t-butanolate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 6-(4-(2-aminopropan-2-yl)pyridin-2-ylamino)-8-(tert-butylamino)-2-(2-hydroxyethyl)-2,7-naphthyridin-1(2H)-one
  参考文献：
  名称：

  [EN] 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS
  [FR] COMPOSÉS ET COMPOSITIONS UTILISÉS COMME INHIBITEURS DE LA SYK KINASE

  摘要：

  本文提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或失调的Syk激酶活性相关的疾病或疾病的方法。

  公开号：

  WO2011014515A1
• 作为产物：
  描述：

  tert-butyl (2-(2-chloropyridin-4-yl)propan-2-yl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 以92 %的产率得到2-(2-chloropyridin-4-yl)propan-2-amine
  参考文献：
  名称：

  [EN] 2,7-NAPHTHYRIDINE COMPOUNDS AS MASTL INHIBITORS
  [FR] COMPOSÉS DE 2,7-NAPHTYRIDINE EN TANT QU'INHIBITEURS DE MASTL

  摘要：

  The invention relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein X and R1to R5are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may inhibit the activities of MASTL receptor and may be useful in the treatment, prevention, suppression and amelioration of cancers, or diseases, disorders and conditions mediated by MASTL receptor.

  公开号：

  WO2024003773A1

文献信息

• COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS
  申请人：CHE Jianwei

  公开号：US20110053897A1

  公开（公告）日：2011-03-03

  Provided herein area novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.

  本文提供了一种新型化合物、包含这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或非调节Syk激酶活性有关的疾病或紊乱的方法。
• 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS
  申请人：IRM LLC

  公开号：EP2459556A1

  公开（公告）日：2012-06-06
• THERAPEUTIC COMPOUNDS
  申请人：[en]SANOFI

  公开号：WO2024121427A1

  公开（公告）日：2024-06-13

  The present disclosure relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.
• [EN] 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILISÉS COMME INHIBITEURS DE LA SYK KINASE
  申请人：IRM LLC

  公开号：WO2011014515A1

  公开（公告）日：2011-02-03

  Provided herein area novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.

  本文提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或失调的Syk激酶活性相关的疾病或疾病的方法。
• [EN] 2,7-NAPHTHYRIDINE COMPOUNDS AS MASTL INHIBITORS<br/>[FR] COMPOSÉS DE 2,7-NAPHTYRIDINE EN TANT QU'INHIBITEURS DE MASTL
  申请人：[en]PFIZER INC.

  公开号：WO2024003773A1

  公开（公告）日：2024-01-04

  The invention relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein X and R1to R5are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may inhibit the activities of MASTL receptor and may be useful in the treatment, prevention, suppression and amelioration of cancers, or diseases, disorders and conditions mediated by MASTL receptor.